A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery

Helga P Sandoval, Luis E Fernández de Castro, David T Vroman, Kerry D Solomon, Helga P Sandoval, Luis E Fernández de Castro, David T Vroman, Kerry D Solomon

Abstract

The non-steroidal anti-inflammatory drug (NSAID) ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation containing 20% less active ingredient that the original formulation, is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Clinical studies have shown ketorolac tromethamine 0.4% to be as effective as ketorolac tromethamine 0.5% to control inflammation after cataract surgery including prevention of cystoid macular edema (CME). Its efficacy to inhibit miosis during cataract surgery as well as its role in the treatment of dry eye has been reported. The purpose of this paper is to review the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.

Keywords: NSAIDs; anti-inflammatory; ketorolac; ocular; ophthalmic.

References

    1. Bishop-Bailey D, Mitchell JA, Warner TD. COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Bio. 2006;26:956–8.
    1. Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32:1474–82.
    1. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987;103:479–86.
    1. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tromethamine 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology. 1988;95:1279–84.
    1. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992;36:259–84.
    1. Furberg CD. The COX-2 inhibitors – An update. Am Heart J. 2006;152:197–9.
    1. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25:233–50.
    1. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936–44.
    1. Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray. Curr Med Res Opin. 2005;21:1217–26.
    1. Holzer MP, Solomon KD, Sandoval HP, et al. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for treatment of inflammation following phacoemulsification: A prospective, randomized, double-masked study. J Cataract Refract Surg. 2002;28:93–9.
    1. Jay GT. Ketorolac tromethamine. Conn Med. 1991;55:288–90.
    1. Jett MF, Ramesha CS, Brown CD, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther. 1999;288:1288–97.
    1. Kosrirukvongs P, Prabhasawat P, Srivannaboon S, et al. Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusis. J Med Assoc Thai. 2001;84:804–10.
    1. Litvak KM, McEvoy GK. Ketorolac, an injectable nonnarcotic analgesic. Clin Pharm. 1990;9:921–35.
    1. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits. J Pharm Sci. 1987;76:289–94.
    1. McDonald MB, Brint SF, Caplan DI, et al. Comparison of ketorolac tromethamine, diclofenac sodium, and moist drops for ocular pain after radial keratotomy. J Cataract Refract Surg. 1999;25:1097–1108.
    1. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75–86.
    1. Nichols J, Snyder R. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998;9:40–4.
    1. Pallapies D, Salinger A, Meyer zum Gottesberge A, et al. Effects of lysine onixinate and ketorolac tromethamine on prostanoid release from various rat organs incubated ex vivo. Life Sci. 1995;57:83–9.
    1. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4% Expert Opin Pharmacother. 2006;7:99–107.
    1. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20:2015–9.
    1. Rajpal RK, Cooperman BB. Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. J Refract Surg. 1999;15:661–7.
    1. Sandoval HP, Fernández de Castro LE, Vroman DT, et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther. 2006;22:251–7.
    1. Schechter BA. Ketorolac during the induction phase of cyclosporin-A therapy. J Ocul Pharmacol Ther. 2006;22:150–4.
    1. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001a;108:331–7.
    1. Solomon KD, Vroman DT, Barker D, et al. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective, randomized, double-masked study. J Cataract Refract Surg. 2001b;27:1232–7.
    1. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg. 2004;30:1653–60.
    1. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg. 1999;25:699–704.
    1. Teal P, Breslin C, Arshinoff S, et al. Corneal subepithelial infiltrates following excimer laser photorefractive keratectomy. J Cataract Refract Surg. 1995;21:516–18.
    1. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804.
    1. Waterbury LD, Flach AJ. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation. J Ocul Pharmacol Ther. 2006;22:155–9.
    1. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133–40.
    1. Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand. 2003;81:378–82.
    1. Yee RW. Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Am J Ophthalmol. 1998;125:472–80.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit